India may host a trial to test so-called artificial blood, or blood substitutes, later this year, a first for a country that is increasingly becoming home to all sorts of human clinical trials.
Arthur Bollon, chief executive of
HemoBioTech Inc., a small firm based in Dallas, Texas, said the India trials of HemoTech, the brand name of the product, will run simultaneously with tests in the US and be a crucial step in giving the world the first viable substitute for human blood.
HemoBioTech, founded in 2001, trades on the Over The Counter Bulletin Board in the US and last traded at $1.26 (about Rs50) a share. The technology, it says, has been licensed from the Texas Tech University Health Science Centre in Lubbock.
More
You are currently accessing this Site as a guest. Please login or register by clicking Here
Linear Mode
